StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by Bully88on Aug 06, 2020 10:43am

122 Views

Post# 31372709

RE:RE:RE:RE:Revenue Projections

THANK YOU

They are charging $75-$125 USD to process the test.

that is their revenue stream.

If you want to discuss profit margins and overhead that is a completely differerent conversation.

Those conversations have already been openly discussed. without bashing or pumping. All Ideas/ concerns welcomed.

My spread is a basic speculative revenue estimate.

Read the writing on the wall. or in this case the Prospectus. Its all in there.

$75-$125 USD paid up front to process the test. They do not need to buy it, make it or sell it.
They are Processing tests given to them and paid for by their massive partners.